Key Stats for Johnson & Johnson Stock
- Price change for Johnson & Johnson stock in last 6 months: 14%
- $JNJ Stock Price as of Oct. 22: $267
- 52-Week High: $281
- $JNJ Stock Price Target: $279
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Smith & Nephew held merger talks with Johnson & Johnson (JNJ) to combine with J&J’s orthopedics division.
The Financial Times reported that the talks collapsed over who would run the new company
Talks were reportedly at an advanced stage, and both sides had agreed on the main financial terms and the deal structure. A mid-October announcement was in sight.
Then the talks fell apart. J&J wanted Namal Nawana to lead the merged business, who currently runs J&J’s orthopedics unit. He also led Smith & Nephew for 18 months before leaving as CEO in 2019.
Smith & Nephew wanted its current CEO, Deepak Nath, to stay in charge.
Smith & Nephew had approached J&J earlier this year, and its offer valued J&J’s hip and knee unit at up to $22 billion.
That is almost double Smith & Nephew’s own market value. J&J shareholders would have owned 50.1% of the combined company.
Both companies declined to comment.
See analysts’ growth forecasts and price targets for Johnson & Johnson stock (It’s free) >>>
What the Market Is Telling Us About Johnson & Johnson Stock
The report is unlikely to move Johnson And Johnson stock much by itself. A Mergermarket analyst said it would not be surprising if the two sides returned to the table.
J&J already has a backup plan and announced last October that it would split off orthopedics as a standalone company called DePuy Synthes.
On its Q3 call, J&J said it is leaning toward a spin-off and is targeting mid-2027 for the separation. A CFO also said the business is performing well.
J&J’s Q3 sales were $25.4 billion, up 6%. Innovative Medicine sales grew 7.9%, MedTech grew only 2.5%, and management said that fell short of expectations.
J&J raised its 2026 sales guidance and now expects growth of 6.7% to 7.1%.
For Johnson And Johnson stock, the open question is how orthopaedics leaves the company.
Reuters says the unit reportedly sought around $20 billion and drew private equity interest. No deal has been reached. Johnson And Johnson stock may stay sensitive to updates on the separation.
J&J will share more at its Enterprise Business Review on December 8. Investors in Johnson And Johnson stock may want to watch that event.
Estimate a company’s fair value instantly (Free with TIKR) >>>
So what is Johnson & Johnson stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what JNJ stock could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Value Johnson & Johnson for free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
